{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:34Z","timestamp":1790395474480,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T00:00:00Z","timestamp":1550275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.nefro.2018.10.017","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T21:21:13Z","timestamp":1552771273000},"page":"294-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nefropat\u00eda por enfermedad de Fabry. Rol del nefr\u00f3logo y variables cl\u00ednicas asociadas al diagn\u00f3stico"],"prefix":"10.1016","volume":"39","author":[{"given":"Sebasti\u00e1n","family":"Jaurretche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Antongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2018.10.017_bib0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: Lysosomal storage disorders: The cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J Cell Biol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0235","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.nefro.2018.10.017_bib0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.nefro.2018.10.017_bib0245","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat."},{"key":"10.1016\/j.nefro.2018.10.017_bib0250","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: A systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J Med Genet."},{"key":"10.1016\/j.nefro.2018.10.017_bib0255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: A key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.nefro.2018.10.017_bib0260","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.nefro.2018.10.017_bib0265","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.017_bib0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1651-2227.2006.tb02392.x","article-title":"Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease","volume":"95","author":"Barbey","year":"2006","journal-title":"Acta Paediatr Suppl."},{"key":"10.1016\/j.nefro.2018.10.017_bib0275","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"T\u00f8ndel","year":"2008","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2018.10.017_bib0280","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.017_bib0285","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","author":"Mehta","year":"2006"},{"key":"10.1016\/j.nefro.2018.10.017_bib0290","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med."},{"key":"10.1016\/j.nefro.2018.10.017_bib0295","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.017_bib0300","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.017_bib0305","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.017_bib0310","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0315","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: A review \u2014 how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0320","first-page":"2","article-title":"Evaluaci\u00f3n pre trasplante renal en el paciente con enfermedad de Fabry","volume":"37","author":"Jaurretche","year":"2016","journal-title":"Dial Traspl."},{"key":"10.1016\/j.nefro.2018.10.017_bib0325","first-page":"1","article-title":"The kidney in Fabry disease: More than mere sphingolipids overload","volume":"4","author":"Trimarchi","year":"2016","journal-title":"JIEMS."},{"key":"10.1016\/j.nefro.2018.10.017_bib0330","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: Data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J Med Genet."},{"key":"10.1016\/j.nefro.2018.10.017_bib0335","series-title":"Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurements","author":"Tondel","year":"2013"},{"key":"10.1016\/j.nefro.2018.10.017_bib0340","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","article-title":"Podocyturia is significantly elevated in untreated vs treated Fabry adult patients","volume":"29","author":"Trimarchi","year":"2016","journal-title":"J Nephrol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0345","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymgme.2017.05.007","article-title":"New biomarkers defining a novel early stage of Fabry nephropathy: A diagnostic test study","volume":"121","author":"Aguiar","year":"2017","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.nefro.2018.10.017_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000444026","article-title":"Renal biopsy in 2015 \u2014 From epidemiology to evidence-based indications","volume":"43","author":"Fiorentino","year":"2016","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0355","first-page":"41","article-title":"Prevalence of chronic kidney disease in Fabry disease patients: Multicenter cross sectional study in Argentina","volume":"12","author":"Jaurretche","year":"2017","journal-title":"Mol Genet Metab Rep."},{"key":"10.1016\/j.nefro.2018.10.017_bib0360","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidaseA gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am J Hum Genet."},{"key":"10.1016\/j.nefro.2018.10.017_bib0365","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2008.03.017","article-title":"Identification of GLA gene deletions in Fabry patients by Multiplex Ligation-dependent Probe Amplification (MLPA)","volume":"94","author":"Schirinzi","year":"2008","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.nefro.2018.10.017_bib0370","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2004.035907","article-title":"Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening","volume":"50","author":"Li","year":"2004","journal-title":"Clin Chem."},{"key":"10.1016\/j.nefro.2018.10.017_bib0375","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: Comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"T\u00f8ndel","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.017_bib0380","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/ndt\/gfq108","article-title":"The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease","volume":"25","author":"Rombach","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2018.10.017_bib0385","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefro.2018.10.017_bib0390","first-page":"613","article-title":"Documento de consenso: Implicancia de la proteinuria en el diagn\u00f3stico y seguimiento de la enfermedad renal cr\u00f3nica","volume":"47","author":"Inserra","year":"2013","journal-title":"Acta Bioqu\u00edm Clin Latinoam."},{"key":"10.1016\/j.nefro.2018.10.017_bib0395","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ki.2012.169","article-title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatinC","volume":"82","author":"Schwartz","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.017_bib0400","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1157\/13116658","article-title":"Cardiovascular risk factors insights from Framingham Heart Study","volume":"61","author":"O\u2019Donnell","year":"2008","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0405","first-page":"1","article-title":"Small fiber neuropathy in Fabry disease: A review of pathophysiology and treatment","volume":"4","author":"Politei","year":"2016","journal-title":"JIEMS."},{"key":"10.1016\/j.nefro.2018.10.017_bib0410","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the gastrointestinal manifestations of Fabry disease: Promoting prompt diagnosis","volume":"9","author":"Zar-Kessler","year":"2016","journal-title":"Therap Adv Gastroenterol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0415","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Ophthalmological manifestations of Fabry disease","author":"Sodi","year":"2006"},{"key":"10.1016\/j.nefro.2018.10.017_bib0420","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","article-title":"Fabry disease and the heart","volume":"29","author":"Seydelmann","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"10.1016\/j.nefro.2018.10.017_bib0425","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.2174\/13816128113199990387","article-title":"Neurological complications of Anderson-Fabry disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.nefro.2018.10.017_bib0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000320903","article-title":"Blood pressure, proteinuria and nephropathy in Fabry disease","volume":"118","author":"Jain","year":"2011","journal-title":"Nephron Clin Pract."},{"key":"10.1016\/j.nefro.2018.10.017_bib0435","unstructured":"Herrero Calvo J. Nefropat\u00eda por Enfermedad de Fabry. En: Lorenzo V, L\u00f3pez G\u00f3mez JM (eds.). Nefrolog\u00eda al D\u00eda. Disponible en: http:\/\/www.revistanefrologia.com\/es-monografias-nefrologia-dia-articulo-nefropatia-por-enfermedad-fabry-149"},{"key":"10.1016\/j.nefro.2018.10.017_bib0440","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0445","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.017_bib0450","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951930044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951930044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:30Z","timestamp":1759323210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021169951930044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S021169951930044X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.017","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nefropat\u00eda por enfermedad de Fabry. Rol del nefr\u00f3logo y variables cl\u00ednicas asociadas al diagn\u00f3stico","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}